Glaxis Capital Management’s Pfizer PFE Stock Holding History

Glaxis Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10,000	Closed	-$289K	–	48
2024 Q3	$289K	Buy	+10,000	New	+$292K	1.12%	27

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Glaxis Capital Management's PFE Position: Q4 2024 in Review

Glaxis Capital Management sold out of Pfizer (PFE) in Q4 2024, closing a stake of 10,000 shares — an estimated $289K sold.

Glaxis Capital Management first reported a position in PFE in Q3 2024 and held it in 1 quarter. The position peaked at $289K in Q3 2024. 2,996 funds tracked by Wall St. Rank hold PFE as of Q4 2024.

Glaxis Capital Management reported no remaining Pfizer position as of Q4 2024 after selling out during the quarter.
Glaxis Capital Management sold 10,000 Pfizer shares in Q4 2024, an estimated $289K.
Glaxis Capital Management first reported a position in Pfizer in Q3 2024 and held it in 1 quarter.
Glaxis Capital Management's Pfizer position peaked at $289K in Q3 2024.
2,996 funds tracked by Wall St. Rank held Pfizer as of Q4 2024.

Based on Glaxis Capital Management's 13F filing for Q4 2024, filed 7 Feb 2025.